Invention Grant
- Patent Title: Gene signature predictive of hepatocellular carcinoma response to transcatheter arterial chemoembolization (TACE)
-
Application No.: US16076239Application Date: 2017-02-07
-
Publication No.: US11306362B2Publication Date: 2022-04-19
- Inventor: Xin Wei Wang , Valerie Fako Miller
- Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Applicant Address: US MD Bethesda
- Assignee: The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Current Assignee: The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Current Assignee Address: US MD Bethesda
- Agency: Klarquist Sparkman, LLP
- International Application: PCT/US2017/016851 WO 20170207
- International Announcement: WO2017/139276 WO 20170817
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; C12Q1/6886
Abstract:
This disclosure provides methods for predicting the likelihood that a hepatocellular carcinoma (HCC) will respond to transcatheter arterial chemoembolization (TACE) using a gene signature of 14 or 15 genes. Also provided are nucleic acid probes and kits for detecting the gene signature.
Public/Granted literature
Information query
